Activation of the complement system,
for liver function which may persist throughout the first decade of life, but only 17% show important clinical features of liver disease. 45 The pathogenic mechanism of liver damage remains unknown, although it has been suggested that the liver disease is caused by the intrahepatocellular accumulation of alAT. But this does not explain why only a minority of those with the PiZZ phenotype develop clinically important liver disease.
Deficiency of alAT may affect the complement system, the main humoral mediator of inflammation.67 alAT is the principal inhibitor of the powerful serine protease, neutrophil elastase, which has a role in the activation of the complement system.8 alAT can inhibit other serine protease activities, including those acquired by components of the complement cascade when activated.910 Thus deficiency of aclAT could result in tissue damage due to unrestrained activation of the complement system whose effects include cell lysis, opsonisation, and chemotaxis of phagocytes.
To investigate the possible association of complement activation with liver disease in a lAT deficiency we measured plasma concentrations of C4, the C3d fragment, its parent molecule C3, derived the C3d:C3 ratio as an index of complement activationl' in children with liver disease of different severities associated with the PiZZ phenotype. Thirty eight healthy children (21 male, 17 female, median age 6-0 years, age range 07-14 7) were studied as controls after the informed consent of their parents and of the older children had been obtained. Peripheral blood was collected by venepuncture into a final ethylene diamine tetra-acetic acid (EDTA) concentration of 10 mmol/l. Following centrifugation at 1000 x g for 15 minutes at 40C, the plasma was separated and stored at -70°C until used.
Liver function tests were carried out when the blood samples were taken (table 1). COMPLEMENT A C3d standard was derived from normal human serum by incubation with 3 mg/ml of inulin at 37°C for one hour, producing exhaustive activation of the alternative pathway C3 convertase." After centrifugation at 1500 x g for 30 minutes the supernatant was aliquoted and used as a C3d standard.
The laser nephelometric method used has been described previously. " Briefly, test plasma Plasma concentrations of C3 and C4 were measured using a nephelometric technique with specific antisera according to the manufacturer's instructions (Boehring, Marburg, Germany). Results were expressed in g/l.
The C3d:C3 ratio was calculated to provide an index of C3 activation that is independent of the initial concentration of the C3 molecule. C-REACTIVE PROTEIN C-reactive protein was measured using a nephelometric technique with specific antisera according to the manufacturer's instructions (Boehring, Marburg, Germany).
Mean results were compared by Student's t test; relations between variables were analysed using the coefficient of correlation r. Data were also analysed using the non-parametric equivalents of the tests used, yielding similar levels of significance.
Results
The results of clAT, C3, C4, C3d and C3d:C3 are presented in the figure and in table 2. As expected, alAT blood concentrations in the patients with the PiZZ phenotype were significantly lower than in the controls. Concentrations in patients with severe liver disease tended to be lower than in patients with moderate liver disease.
C4 and C3 concentrations were significantly lower in patients with severe liver disease compared with those with moderate-or minimal liver disease and in normal controls. C3 concentrations were also significantly higher in patients with moderate or minimal liver disease than in controls, the highest concentrations being in those with moderate disease. C4 concentrations, although following a similar pattern, were not significantly higher in patients with minimal liver disease than in controls.
In the entire patient group C3 and C4 concentrations correlated positively with each other (r = .0-85, p < 0 0001) and with xlAT x,-antitrypsin deficiency, complement activation, and chronic liver disease concentrations (r = 0 57, p = 0-00038 and r = 0 35, p = 0 039, respectively). In the entire patient group the C3d:C3 ratio correlated negatively with albumin concentration (r = -0 62, p = 0-00008) and positively with alkaline phosphatase (r = 0-45, p = 0 008), GGT (r = 0-45, p = 0-01), and aspartate aminotransferase concentrations (r = 0 32, p = 0-07).
alAT concentrations did not correlate with C3d:C3 ratio within either the entire patient group, the group with severe liver disease, or the control group.
All but one of the 37 normal controls and all 31 patients with oa 1AT deficiency tested had Creactive protein values below the upper limit of normal of 1 mg/dl. C-reactive concentrations below the detection limit of 0-25 mg/dl were seen in 32 of 37 controls and in 24 of 31 patients. There was no difference between patients and controls.
Discussion
This study provides evidence that liver disease associated with alAT deficiency is associated with an increase in complement activation, as shown by the C3d:C3 ratio being significantly higher in patients than in controls. Our data also suggest an association between increasing severity of liver disease and increasing degrees of complement activation, as shown by the C3d:C3 ratio being highest in patients with severe liver disease, and by the correlations of C3d:C3 values with other markers of liver damage: albumin, alkaline phosphatase, GGT and aspartate aminotransferase activities.
The C3d:C3 ratio is an index of C3 activation independent of initial concentrations of the parent C3 molecule, and hence the higher C3d:C3 ratio in patients with severe liver disease indicates that there was greater activation of the parent C3 molecules whose concentration was dwindling. The low concentrations of C3 in these patients may reflect complement consumption or reduced production due to a decline in the number of functioning hepatocytes, the latter hypothesis being supported by the simultaneous decrease in the concentrations of C4, albumin, and alAT, which are all produced in the liver."3 An alternative explanation for the lowest concentrations of alAT being observed in patients with cirrhosis may be that the more severely impaired the production of alAT, the more serious the liver damage. Why patients with minimal or moderate liver disease have increased C3 concentrations is unclear. Although it is tempting to attribute this increase to the known behaviour of C3 as an acute phase reactant, this explanation is questioned by the finding that C-reactive protein concentrations in the patients were similar to control values.
There are several possible mechanisms by which alAT deficiency might lead to complement activation. Trypsin-like enzymes such as elastase activate both the classical and alternative pathways8 which merge at the stage of C3. It is conceivable that elastase or trypsin, which are normally inhibited in the blood by alAT, may cause complement activation in those with alAT deficiency. Previous reports have also shown that czlAT could inhibit the serine protease activity of classical and alternative pathway components, including Cls, Clr, and factor D.9 This suggests that alAT deficiency may lead to a decrease in inhibition and hence an increase in activation of the complement system, with consequent production of mediators of inflammation. Although these mediators were not directly estimated in this study, we did measure the concentrations of the activation fragment C3d. This is produced on an equimolar basis with the biologically active C3a but has a prolonged half-life, leaving a longer lasting trace of complement activation. '4 Complement activation may not merely be associated with liver disease associated with cx AT deficiency but it may be a major effector of the liver damage, perhaps through tissue inflammation, cell lysis, or recruitment of phagocytes. The PiZZ phenotype, causing intracellular accumulation of oclAT and deficient blood concentrations, predisposes an individual to develop liver disease in infancy, but the fact that only a minority of children born with the PiZZ phenotype show clinical features of liver disease suggests that cxlAT accumulation is not the prime or sole effector of liver damage.
The absence of a correlation between alAT activity and the C3d:C3 ratio may mean that a lAT is not directly associated with C3 activation. The behaviour of C3'5 and acAT3 as acute phase reactants, however, and the difference in the half-lives of C3d'4 and axlAT3 could conceal any direct correlation between cxlAT and the C3 activation ratio. Furthermore, cxlAT concentrations may be associated with activation of the complement system at an earlier point in either the classical or alternative pathways of the cascade.
Activation of the complement system is under the control of other inhibitors, stimulators, and genetic and environmental factors,"6 and differences in any of these could determine who of those with the PiZZ phenotype develops liver disease. If complement activation does have a role in the liver damage associated with a 1AT deficiency then the reason why the liver and not other organs are affected in infancy remains to be established. One can speculate that environmental factors, such as toxins or hepatotropic viruses, or additional genetic factors, such as the possession of the HLA DR3-Dw25 allele'7 may be implicated in this liver specificity.
This study, which is based on a cross-section of patients with alAT deficiency and liver disease, suggests that there is an association between the degree of complement activation and the severity of liver damage. Whether the association is due to complement activation causing liver damage, or to the liver damage causing complement to be activated, remains to be elucidated.
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